| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prosthesis-Related Infections | 58 | 2025 | 188 | 14.400 |
Why?
|
| Defibrillators, Implantable | 53 | 2025 | 200 | 13.710 |
Why?
|
| Pacemaker, Artificial | 45 | 2025 | 179 | 11.410 |
Why?
|
| Endocarditis | 30 | 2022 | 107 | 7.410 |
Why?
|
| Endocarditis, Bacterial | 23 | 2022 | 137 | 6.570 |
Why?
|
| Bacteremia | 25 | 2025 | 430 | 6.260 |
Why?
|
| Staphylococcal Infections | 24 | 2021 | 573 | 5.040 |
Why?
|
| Anti-Bacterial Agents | 63 | 2025 | 2575 | 4.570 |
Why?
|
| Nanoparticles | 23 | 2025 | 289 | 4.140 |
Why?
|
| Chitosan | 11 | 2022 | 32 | 2.630 |
Why?
|
| Staphylococcus aureus | 17 | 2025 | 480 | 2.210 |
Why?
|
| Rhinoplasty | 3 | 2024 | 46 | 2.120 |
Why?
|
| Drug Carriers | 12 | 2023 | 119 | 2.120 |
Why?
|
| Drug Delivery Systems | 15 | 2025 | 232 | 2.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 6 | 2025 | 151 | 1.970 |
Why?
|
| Water Pollutants, Chemical | 4 | 2025 | 40 | 1.950 |
Why?
|
| Humans | 223 | 2025 | 133182 | 1.870 |
Why?
|
| Metal Nanoparticles | 6 | 2021 | 59 | 1.810 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 8 | 2023 | 230 | 1.770 |
Why?
|
| Acinetobacter | 3 | 2020 | 9 | 1.750 |
Why?
|
| Cross Infection | 5 | 2018 | 344 | 1.740 |
Why?
|
| Polychlorinated Biphenyls | 3 | 2023 | 12 | 1.720 |
Why?
|
| Hydrocarbons, Chlorinated | 3 | 2023 | 14 | 1.700 |
Why?
|
| Pakistan | 21 | 2025 | 95 | 1.690 |
Why?
|
| Device Removal | 20 | 2025 | 223 | 1.650 |
Why?
|
| Heart Valve Prosthesis | 5 | 2022 | 314 | 1.630 |
Why?
|
| Bacterial Adhesion | 4 | 2020 | 106 | 1.550 |
Why?
|
| Pesticides | 2 | 2023 | 30 | 1.540 |
Why?
|
| Hot Temperature | 3 | 2022 | 145 | 1.540 |
Why?
|
| Aged | 82 | 2025 | 21448 | 1.520 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 136 | 1.500 |
Why?
|
| Male | 123 | 2025 | 65478 | 1.410 |
Why?
|
| Soil Pollutants | 4 | 2024 | 13 | 1.400 |
Why?
|
| Biofilms | 3 | 2025 | 99 | 1.390 |
Why?
|
| Hydrogels | 14 | 2023 | 109 | 1.390 |
Why?
|
| Immunocompromised Host | 5 | 2019 | 305 | 1.350 |
Why?
|
| Acinetobacter Infections | 4 | 2022 | 36 | 1.350 |
Why?
|
| Anti-Infective Agents | 8 | 2025 | 275 | 1.350 |
Why?
|
| Cellulose | 6 | 2024 | 30 | 1.330 |
Why?
|
| Antifungal Agents | 9 | 2022 | 306 | 1.280 |
Why?
|
| Bacterial Infections | 6 | 2021 | 328 | 1.270 |
Why?
|
| Microbial Sensitivity Tests | 18 | 2025 | 835 | 1.240 |
Why?
|
| Middle Aged | 74 | 2025 | 28912 | 1.230 |
Why?
|
| Equipment Contamination | 3 | 2020 | 41 | 1.220 |
Why?
|
| Air Pollutants | 2 | 2023 | 115 | 1.200 |
Why?
|
| Salmonella typhi | 3 | 2025 | 21 | 1.200 |
Why?
|
| Histoplasmosis | 3 | 2019 | 49 | 1.200 |
Why?
|
| Gram-Positive Bacterial Infections | 6 | 2019 | 80 | 1.200 |
Why?
|
| Bacterial Proteins | 4 | 2025 | 924 | 1.200 |
Why?
|
| Endo-1,4-beta Xylanases | 3 | 2025 | 5 | 1.180 |
Why?
|
| Echocardiography, Transesophageal | 9 | 2021 | 258 | 1.160 |
Why?
|
| Bacillaceae | 2 | 2025 | 2 | 1.150 |
Why?
|
| Lyme Disease | 2 | 2019 | 37 | 1.140 |
Why?
|
| Heart-Assist Devices | 5 | 2019 | 1099 | 1.120 |
Why?
|
| Nasal Septum | 2 | 2024 | 20 | 1.100 |
Why?
|
| Saccharum | 3 | 2023 | 12 | 1.100 |
Why?
|
| Female | 106 | 2025 | 71396 | 1.090 |
Why?
|
| Gram-Negative Bacteria | 4 | 2019 | 74 | 1.090 |
Why?
|
| Adult | 59 | 2025 | 31616 | 1.080 |
Why?
|
| Polymers | 7 | 2024 | 118 | 1.070 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 79 | 1.070 |
Why?
|
| Retrospective Studies | 53 | 2024 | 17526 | 1.020 |
Why?
|
| Fever | 4 | 2019 | 312 | 1.010 |
Why?
|
| Chenopodiaceae | 2 | 2025 | 2 | 1.010 |
Why?
|
| Cleft Lip | 2 | 2023 | 133 | 1.000 |
Why?
|
| Catheter-Related Infections | 2 | 2018 | 139 | 0.990 |
Why?
|
| Surgical Wound Infection | 4 | 2020 | 272 | 0.980 |
Why?
|
| Models, Theoretical | 3 | 2022 | 395 | 0.970 |
Why?
|
| Kidney Failure, Chronic | 3 | 2022 | 906 | 0.960 |
Why?
|
| Environmental Monitoring | 4 | 2023 | 91 | 0.960 |
Why?
|
| Coriandrum | 1 | 2025 | 1 | 0.950 |
Why?
|
| Ipomoea | 1 | 2025 | 1 | 0.950 |
Why?
|
| Nanostructures | 2 | 2022 | 65 | 0.940 |
Why?
|
| Thiazoles | 2 | 2018 | 104 | 0.930 |
Why?
|
| Wound Healing | 9 | 2024 | 483 | 0.920 |
Why?
|
| Diarrhea | 2 | 2018 | 339 | 0.910 |
Why?
|
| Nose Deformities, Acquired | 1 | 2024 | 12 | 0.910 |
Why?
|
| Trametes | 1 | 2024 | 1 | 0.890 |
Why?
|
| Textiles | 1 | 2024 | 11 | 0.880 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 677 | 0.870 |
Why?
|
| Antibiotic Prophylaxis | 4 | 2018 | 128 | 0.860 |
Why?
|
| Hospitalization | 9 | 2021 | 1910 | 0.860 |
Why?
|
| Plasmids | 1 | 2025 | 529 | 0.860 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2020 | 475 | 0.850 |
Why?
|
| Antiviral Agents | 8 | 2021 | 823 | 0.850 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 1849 | 0.840 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 318 | 0.830 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2025 | 180 | 0.830 |
Why?
|
| Gentamicins | 3 | 2023 | 95 | 0.820 |
Why?
|
| Diagnostic Imaging | 3 | 2020 | 317 | 0.820 |
Why?
|
| Plant Extracts | 4 | 2021 | 138 | 0.820 |
Why?
|
| Biological Availability | 9 | 2022 | 151 | 0.810 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 7137 | 0.790 |
Why?
|
| Manure | 1 | 2022 | 6 | 0.790 |
Why?
|
| Biofuels | 1 | 2022 | 8 | 0.780 |
Why?
|
| Aspergillus fumigatus | 2 | 2017 | 44 | 0.770 |
Why?
|
| Hyaluronic Acid | 6 | 2024 | 109 | 0.760 |
Why?
|
| Mucormycosis | 3 | 2017 | 32 | 0.760 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 80 | 0.760 |
Why?
|
| Hydrodynamics | 1 | 2022 | 28 | 0.760 |
Why?
|
| Risk Factors | 29 | 2021 | 10935 | 0.730 |
Why?
|
| Administration, Oral | 10 | 2021 | 718 | 0.720 |
Why?
|
| Young Adult | 28 | 2025 | 9921 | 0.710 |
Why?
|
| Psoas Abscess | 1 | 2021 | 3 | 0.710 |
Why?
|
| Referral and Consultation | 1 | 2025 | 572 | 0.710 |
Why?
|
| Silver | 4 | 2021 | 30 | 0.710 |
Why?
|
| Actinobacteria | 1 | 2021 | 13 | 0.710 |
Why?
|
| Wound Infection | 2 | 2021 | 57 | 0.700 |
Why?
|
| Burns | 4 | 2024 | 101 | 0.700 |
Why?
|
| Ionic Liquids | 1 | 2020 | 3 | 0.700 |
Why?
|
| Animals | 46 | 2025 | 36185 | 0.690 |
Why?
|
| Polysaccharides | 2 | 2024 | 152 | 0.690 |
Why?
|
| Treatment Outcome | 30 | 2024 | 13094 | 0.680 |
Why?
|
| Bacillus | 1 | 2020 | 37 | 0.680 |
Why?
|
| Polymyxins | 1 | 2020 | 15 | 0.680 |
Why?
|
| Data Accuracy | 1 | 2020 | 34 | 0.670 |
Why?
|
| Algorithms | 5 | 2024 | 1730 | 0.670 |
Why?
|
| Transplant Recipients | 2 | 2019 | 227 | 0.670 |
Why?
|
| Risk Assessment | 16 | 2024 | 3715 | 0.670 |
Why?
|
| Spinal Cord Stimulation | 1 | 2020 | 9 | 0.670 |
Why?
|
| beta-Lactamases | 2 | 2025 | 212 | 0.660 |
Why?
|
| Xylenes | 1 | 2020 | 13 | 0.660 |
Why?
|
| Transdermal Patch | 1 | 2020 | 8 | 0.660 |
Why?
|
| Sulfhydryl Compounds | 5 | 2020 | 61 | 0.660 |
Why?
|
| beta-Lactam Resistance | 2 | 2017 | 49 | 0.660 |
Why?
|
| Renal Dialysis | 3 | 2022 | 892 | 0.660 |
Why?
|
| Frailty | 1 | 2022 | 134 | 0.650 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 171 | 0.650 |
Why?
|
| Cellulitis | 2 | 2017 | 63 | 0.650 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2020 | 38 | 0.650 |
Why?
|
| Gram-Positive Bacteria | 2 | 2019 | 49 | 0.640 |
Why?
|
| Community-Acquired Infections | 3 | 2018 | 247 | 0.630 |
Why?
|
| Anaplasmosis | 1 | 2019 | 2 | 0.630 |
Why?
|
| Myalgia | 1 | 2019 | 10 | 0.620 |
Why?
|
| Musculoskeletal Pain | 1 | 2019 | 16 | 0.620 |
Why?
|
| Clostridium Infections | 2 | 2014 | 251 | 0.620 |
Why?
|
| Pain | 3 | 2020 | 469 | 0.620 |
Why?
|
| Tacrolimus | 1 | 2020 | 105 | 0.620 |
Why?
|
| Publishing | 1 | 2020 | 115 | 0.610 |
Why?
|
| Multimodal Imaging | 2 | 2020 | 113 | 0.610 |
Why?
|
| Metformin | 1 | 2021 | 166 | 0.610 |
Why?
|
| Cryptococcosis | 1 | 2019 | 44 | 0.610 |
Why?
|
| Biological Products | 1 | 2021 | 139 | 0.600 |
Why?
|
| Nanocapsules | 1 | 2018 | 8 | 0.590 |
Why?
|
| Enteritis | 1 | 2018 | 37 | 0.590 |
Why?
|
| Aircraft | 2 | 2011 | 22 | 0.590 |
Why?
|
| Minnesota | 11 | 2021 | 181 | 0.590 |
Why?
|
| Adenoviridae Infections | 1 | 2018 | 69 | 0.580 |
Why?
|
| Metals, Heavy | 3 | 2024 | 23 | 0.580 |
Why?
|
| Biocompatible Materials | 5 | 2023 | 127 | 0.580 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 385 | 0.570 |
Why?
|
| Taxoids | 1 | 2018 | 72 | 0.570 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 395 | 0.570 |
Why?
|
| Larynx | 1 | 2019 | 78 | 0.570 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 19 | 0.570 |
Why?
|
| Dust | 1 | 2017 | 15 | 0.560 |
Why?
|
| Diagnosis, Differential | 10 | 2018 | 1964 | 0.560 |
Why?
|
| Borrelia burgdorferi | 1 | 2018 | 21 | 0.560 |
Why?
|
| Postoperative Complications | 6 | 2019 | 3169 | 0.560 |
Why?
|
| Cost of Illness | 1 | 2020 | 277 | 0.560 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 27 | 0.560 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2017 | 9 | 0.550 |
Why?
|
| Folic Acid | 2 | 2023 | 291 | 0.550 |
Why?
|
| Bartonella Infections | 1 | 2017 | 7 | 0.550 |
Why?
|
| Bartonella henselae | 1 | 2017 | 18 | 0.550 |
Why?
|
| Triazoles | 2 | 2017 | 142 | 0.550 |
Why?
|
| Costal Cartilage | 1 | 2017 | 5 | 0.550 |
Why?
|
| Cardiologists | 1 | 2017 | 24 | 0.540 |
Why?
|
| Shock, Septic | 1 | 2019 | 157 | 0.540 |
Why?
|
| Mediastinum | 1 | 2017 | 47 | 0.540 |
Why?
|
| Heart Failure | 4 | 2022 | 2428 | 0.540 |
Why?
|
| Firmicutes | 1 | 2017 | 22 | 0.540 |
Why?
|
| Herpes Zoster | 1 | 2017 | 26 | 0.540 |
Why?
|
| Travel | 2 | 2011 | 125 | 0.540 |
Why?
|
| Medicare | 3 | 2020 | 468 | 0.540 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 182 | 0.540 |
Why?
|
| Amphotericin B | 4 | 2019 | 91 | 0.530 |
Why?
|
| Nephritis, Interstitial | 1 | 2017 | 40 | 0.530 |
Why?
|
| Carbapenems | 4 | 2025 | 43 | 0.530 |
Why?
|
| Fluoroquinolones | 1 | 2017 | 97 | 0.530 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 1163 | 0.530 |
Why?
|
| Brain Abscess | 1 | 2017 | 54 | 0.530 |
Why?
|
| Hypokalemia | 1 | 2017 | 41 | 0.520 |
Why?
|
| Temporal Lobe | 1 | 2017 | 118 | 0.520 |
Why?
|
| Hypromellose Derivatives | 4 | 2021 | 4 | 0.520 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 121 | 0.520 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 86 | 0.520 |
Why?
|
| Lip | 1 | 2016 | 16 | 0.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 904 | 0.510 |
Why?
|
| Fluorescein Angiography | 1 | 2017 | 154 | 0.510 |
Why?
|
| Bacteria | 4 | 2022 | 536 | 0.510 |
Why?
|
| Sepsis | 1 | 2021 | 522 | 0.510 |
Why?
|
| Incidence | 13 | 2021 | 3385 | 0.510 |
Why?
|
| Sclerotherapy | 1 | 2016 | 40 | 0.510 |
Why?
|
| Abdominal Pain | 3 | 2015 | 313 | 0.510 |
Why?
|
| Cardiovascular Infections | 3 | 2017 | 7 | 0.510 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2017 | 13 | 0.500 |
Why?
|
| Zinc Oxide | 3 | 2020 | 12 | 0.500 |
Why?
|
| Streptococcal Infections | 6 | 2021 | 248 | 0.500 |
Why?
|
| Coinfection | 2 | 2019 | 182 | 0.490 |
Why?
|
| Adenoviridae | 1 | 2018 | 604 | 0.490 |
Why?
|
| Finite Element Analysis | 4 | 2022 | 36 | 0.480 |
Why?
|
| Drug Liberation | 11 | 2024 | 36 | 0.480 |
Why?
|
| Surgical Flaps | 2 | 2021 | 196 | 0.480 |
Why?
|
| Arthroplasty | 1 | 2015 | 17 | 0.480 |
Why?
|
| Patient Satisfaction | 4 | 2024 | 489 | 0.480 |
Why?
|
| Antiprotozoal Agents | 4 | 2020 | 42 | 0.470 |
Why?
|
| Safety | 2 | 2018 | 217 | 0.470 |
Why?
|
| Blood Culture | 3 | 2021 | 36 | 0.470 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2015 | 46 | 0.470 |
Why?
|
| Comorbidity | 10 | 2018 | 1620 | 0.470 |
Why?
|
| Virus Diseases | 1 | 2018 | 291 | 0.470 |
Why?
|
| Vision Disorders | 1 | 2017 | 219 | 0.470 |
Why?
|
| Golgi Apparatus | 1 | 2015 | 96 | 0.460 |
Why?
|
| Health Expenditures | 1 | 2016 | 117 | 0.460 |
Why?
|
| Adolescent | 22 | 2025 | 20549 | 0.460 |
Why?
|
| Vascular Malformations | 1 | 2016 | 111 | 0.460 |
Why?
|
| Rats | 9 | 2021 | 3850 | 0.460 |
Why?
|
| Particle Size | 9 | 2022 | 148 | 0.450 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 276 | 0.450 |
Why?
|
| Bandages | 4 | 2024 | 58 | 0.450 |
Why?
|
| Trichinella | 1 | 2014 | 2 | 0.440 |
Why?
|
| Cytokines | 1 | 2020 | 1377 | 0.440 |
Why?
|
| Trichinellosis | 1 | 2014 | 14 | 0.440 |
Why?
|
| Population Surveillance | 5 | 2018 | 415 | 0.440 |
Why?
|
| Propionibacterium | 2 | 2016 | 4 | 0.440 |
Why?
|
| Albendazole | 1 | 2014 | 29 | 0.440 |
Why?
|
| Clostridium | 1 | 2014 | 17 | 0.440 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 257 | 0.430 |
Why?
|
| Uterine Myomectomy | 1 | 2014 | 12 | 0.430 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 224 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2015 | 239 | 0.430 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2013 | 4 | 0.420 |
Why?
|
| Prostheses and Implants | 3 | 2020 | 153 | 0.420 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 72 | 0.420 |
Why?
|
| Stroke | 1 | 2022 | 1079 | 0.420 |
Why?
|
| Rabbits | 5 | 2022 | 709 | 0.420 |
Why?
|
| Albuminuria | 1 | 2014 | 114 | 0.420 |
Why?
|
| Strongyloidiasis | 1 | 2013 | 16 | 0.420 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2017 | 45 | 0.420 |
Why?
|
| Strongyloides stercoralis | 1 | 2013 | 19 | 0.420 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 936 | 0.420 |
Why?
|
| Haemophilus parainfluenzae | 1 | 2013 | 11 | 0.410 |
Why?
|
| Graphite | 2 | 2025 | 14 | 0.410 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 574 | 0.410 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2020 | 120 | 0.400 |
Why?
|
| Leiomyoma | 1 | 2014 | 83 | 0.400 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2025 | 384 | 0.400 |
Why?
|
| Leishmaniasis | 3 | 2017 | 40 | 0.400 |
Why?
|
| Embolism | 1 | 2013 | 47 | 0.400 |
Why?
|
| Carrageenan | 2 | 2023 | 6 | 0.400 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 5435 | 0.400 |
Why?
|
| Typhoid Fever | 2 | 2024 | 19 | 0.400 |
Why?
|
| Haemophilus Infections | 1 | 2013 | 96 | 0.390 |
Why?
|
| Alternative Splicing | 1 | 2015 | 378 | 0.390 |
Why?
|
| Uterine Neoplasms | 1 | 2014 | 112 | 0.390 |
Why?
|
| Osteomyelitis | 1 | 2015 | 214 | 0.390 |
Why?
|
| Rivers | 2 | 2023 | 16 | 0.390 |
Why?
|
| Delayed-Action Preparations | 9 | 2022 | 124 | 0.390 |
Why?
|
| Soil | 5 | 2024 | 72 | 0.390 |
Why?
|
| Pancytopenia | 1 | 2012 | 41 | 0.380 |
Why?
|
| Cattle | 3 | 2022 | 587 | 0.380 |
Why?
|
| Surgical Mesh | 3 | 2018 | 72 | 0.380 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 649 | 0.380 |
Why?
|
| Abscess | 4 | 2018 | 140 | 0.380 |
Why?
|
| Hypertension | 2 | 2020 | 1402 | 0.380 |
Why?
|
| Cellulase | 2 | 2022 | 5 | 0.370 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 13 | 0.370 |
Why?
|
| Herpes Genitalis | 1 | 2011 | 10 | 0.370 |
Why?
|
| Survival Rate | 9 | 2014 | 2204 | 0.370 |
Why?
|
| Curcumin | 2 | 2022 | 42 | 0.370 |
Why?
|
| Nanomedicine | 4 | 2019 | 26 | 0.360 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2011 | 45 | 0.360 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 195 | 0.360 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2011 | 42 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 772 | 0.350 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 403 | 0.350 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3735 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 3 | 2021 | 1582 | 0.350 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2016 | 61 | 0.340 |
Why?
|
| Cardiovascular Diseases | 3 | 2013 | 2092 | 0.340 |
Why?
|
| Miniaturization | 3 | 2020 | 26 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2014 | 489 | 0.330 |
Why?
|
| Brain Diseases | 1 | 2013 | 308 | 0.330 |
Why?
|
| Disease Management | 3 | 2020 | 565 | 0.330 |
Why?
|
| Prospective Studies | 11 | 2020 | 6571 | 0.330 |
Why?
|
| Curcuma | 2 | 2020 | 2 | 0.330 |
Why?
|
| Ultrasonography | 1 | 2015 | 998 | 0.320 |
Why?
|
| Glucans | 4 | 2022 | 15 | 0.320 |
Why?
|
| Viridans Streptococci | 3 | 2015 | 8 | 0.320 |
Why?
|
| Nose | 2 | 2023 | 105 | 0.320 |
Why?
|
| Time Factors | 11 | 2019 | 6541 | 0.320 |
Why?
|
| Critical Care | 2 | 2014 | 698 | 0.320 |
Why?
|
| Disease Transmission, Infectious | 3 | 2021 | 87 | 0.310 |
Why?
|
| Ceftriaxone | 3 | 2018 | 70 | 0.310 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 2751 | 0.310 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 3043 | 0.310 |
Why?
|
| United States | 13 | 2020 | 11711 | 0.300 |
Why?
|
| Vancomycin | 4 | 2022 | 236 | 0.300 |
Why?
|
| Rejuvenation | 2 | 2019 | 12 | 0.300 |
Why?
|
| Length of Stay | 6 | 2024 | 1392 | 0.300 |
Why?
|
| Solubility | 4 | 2022 | 139 | 0.300 |
Why?
|
| Pandemics | 3 | 2021 | 1192 | 0.290 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 1163 | 0.290 |
Why?
|
| Leishmania | 3 | 2017 | 35 | 0.290 |
Why?
|
| Leishmaniasis, Visceral | 2 | 2019 | 20 | 0.290 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 151 | 0.290 |
Why?
|
| Biomass | 2 | 2025 | 23 | 0.290 |
Why?
|
| Enzyme Stability | 2 | 2025 | 60 | 0.280 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2019 | 62 | 0.280 |
Why?
|
| Membranes, Artificial | 3 | 2025 | 30 | 0.280 |
Why?
|
| Prosthesis Implantation | 3 | 2016 | 152 | 0.280 |
Why?
|
| Skin | 3 | 2020 | 542 | 0.280 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 190 | 0.280 |
Why?
|
| Infection Control | 2 | 2020 | 161 | 0.280 |
Why?
|
| Cell Differentiation | 1 | 2015 | 2026 | 0.270 |
Why?
|
| Age Distribution | 3 | 2016 | 426 | 0.270 |
Why?
|
| Prevalence | 8 | 2025 | 2627 | 0.270 |
Why?
|
| Triticum | 2 | 2024 | 39 | 0.270 |
Why?
|
| Leprosy, Lepromatous | 1 | 2007 | 2 | 0.270 |
Why?
|
| Tuberculosis | 3 | 2023 | 554 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2190 | 0.270 |
Why?
|
| Water | 3 | 2024 | 199 | 0.270 |
Why?
|
| Alginates | 3 | 2023 | 25 | 0.270 |
Why?
|
| Polygalacturonase | 2 | 2024 | 3 | 0.270 |
Why?
|
| Prognosis | 7 | 2020 | 5032 | 0.270 |
Why?
|
| Esthetics | 2 | 2024 | 38 | 0.260 |
Why?
|
| Tensile Strength | 3 | 2024 | 46 | 0.260 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 676 | 0.260 |
Why?
|
| Antioxidants | 3 | 2025 | 366 | 0.260 |
Why?
|
| Sheep | 2 | 2022 | 232 | 0.250 |
Why?
|
| Green Chemistry Technology | 3 | 2021 | 3 | 0.250 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2022 | 314 | 0.250 |
Why?
|
| Polyvinyl Alcohol | 3 | 2023 | 12 | 0.250 |
Why?
|
| Thermal Conductivity | 2 | 2022 | 2 | 0.250 |
Why?
|
| Cohort Studies | 12 | 2021 | 5191 | 0.250 |
Why?
|
| Nitro Compounds | 2 | 2018 | 19 | 0.240 |
Why?
|
| Otitis Media, Suppurative | 1 | 2025 | 5 | 0.240 |
Why?
|
| Odds Ratio | 3 | 2014 | 1253 | 0.240 |
Why?
|
| Coccidioides | 1 | 2005 | 2 | 0.240 |
Why?
|
| Serratia Infections | 1 | 2025 | 6 | 0.240 |
Why?
|
| Lead | 1 | 2025 | 24 | 0.240 |
Why?
|
| Serratia marcescens | 1 | 2025 | 11 | 0.240 |
Why?
|
| Allyl Compounds | 1 | 2025 | 1 | 0.240 |
Why?
|
| Genomic Islands | 1 | 2025 | 30 | 0.240 |
Why?
|
| Mercury | 1 | 2025 | 30 | 0.240 |
Why?
|
| Coccidioidomycosis | 1 | 2005 | 12 | 0.240 |
Why?
|
| Infant, Newborn | 8 | 2017 | 8627 | 0.240 |
Why?
|
| CRISPR-Cas Systems | 3 | 2022 | 298 | 0.240 |
Why?
|
| Male Urogenital Diseases | 1 | 2005 | 16 | 0.240 |
Why?
|
| X-Ray Diffraction | 6 | 2021 | 105 | 0.240 |
Why?
|
| Adipose Tissue | 2 | 2019 | 509 | 0.230 |
Why?
|
| Prosthesis Failure | 2 | 2017 | 162 | 0.230 |
Why?
|
| Water Purification | 1 | 2025 | 18 | 0.230 |
Why?
|
| Sulfides | 1 | 2025 | 24 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 86 | 0.230 |
Why?
|
| Sewage | 1 | 2024 | 11 | 0.230 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 748 | 0.230 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 1462 | 0.230 |
Why?
|
| Echocardiography | 4 | 2021 | 1127 | 0.230 |
Why?
|
| Child | 11 | 2025 | 25847 | 0.230 |
Why?
|
| Phylogeny | 2 | 2025 | 780 | 0.230 |
Why?
|
| Lignin | 2 | 2024 | 18 | 0.230 |
Why?
|
| Injections | 3 | 2023 | 156 | 0.230 |
Why?
|
| Cell Survival | 4 | 2021 | 883 | 0.220 |
Why?
|
| Cobalt Radioisotopes | 1 | 2024 | 3 | 0.220 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 2024 | 11 | 0.220 |
Why?
|
| Virulence | 1 | 2025 | 278 | 0.220 |
Why?
|
| Early Diagnosis | 1 | 2025 | 197 | 0.220 |
Why?
|
| Waste Disposal, Fluid | 1 | 2024 | 7 | 0.220 |
Why?
|
| Fermentation | 2 | 2023 | 71 | 0.220 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2004 | 25 | 0.220 |
Why?
|
| Indocyanine Green | 1 | 2024 | 62 | 0.220 |
Why?
|
| Pneumonia | 3 | 2021 | 341 | 0.220 |
Why?
|
| Heparin | 2 | 2022 | 230 | 0.220 |
Why?
|
| Abdominal Abscess | 1 | 2004 | 27 | 0.220 |
Why?
|
| Skin Transplantation | 1 | 2024 | 57 | 0.220 |
Why?
|
| Pseudomonas Infections | 1 | 2025 | 122 | 0.220 |
Why?
|
| Injections, Intra-Articular | 1 | 2004 | 34 | 0.220 |
Why?
|
| Zea mays | 1 | 2024 | 44 | 0.220 |
Why?
|
| Triamcinolone Acetonide | 1 | 2004 | 36 | 0.220 |
Why?
|
| Hernia, Inguinal | 1 | 2004 | 45 | 0.220 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2004 | 44 | 0.210 |
Why?
|
| Aspergillosis | 1 | 2004 | 46 | 0.210 |
Why?
|
| Parents | 1 | 2011 | 1073 | 0.210 |
Why?
|
| Genome, Bacterial | 1 | 2025 | 213 | 0.210 |
Why?
|
| Polyethylene Glycols | 3 | 2022 | 254 | 0.210 |
Why?
|
| Shoulder Joint | 1 | 2004 | 31 | 0.210 |
Why?
|
| Electronics | 2 | 2020 | 45 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 997 | 0.210 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 288 | 0.210 |
Why?
|
| Engineering | 1 | 2023 | 7 | 0.210 |
Why?
|
| Tertiary Care Centers | 2 | 2022 | 270 | 0.210 |
Why?
|
| Peptones | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2022 | 457 | 0.210 |
Why?
|
| Fluconazole | 2 | 2019 | 50 | 0.210 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 232 | 0.210 |
Why?
|
| Virulence Factors | 1 | 2025 | 187 | 0.210 |
Why?
|
| Meningoencephalitis | 1 | 2003 | 22 | 0.210 |
Why?
|
| Equipment Design | 3 | 2020 | 604 | 0.210 |
Why?
|
| Bone Regeneration | 1 | 2023 | 24 | 0.210 |
Why?
|
| Phantoms, Imaging | 1 | 2024 | 142 | 0.210 |
Why?
|
| Radium | 1 | 2023 | 6 | 0.210 |
Why?
|
| Soil Pollutants, Radioactive | 1 | 2023 | 4 | 0.210 |
Why?
|
| Plastics | 1 | 2023 | 13 | 0.210 |
Why?
|
| Radiation Monitoring | 1 | 2023 | 16 | 0.210 |
Why?
|
| Materials Testing | 2 | 2020 | 77 | 0.210 |
Why?
|
| Pyoderma | 1 | 2023 | 2 | 0.210 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 325 | 0.200 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 3794 | 0.200 |
Why?
|
| Microspheres | 2 | 2021 | 74 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2024 | 301 | 0.200 |
Why?
|
| Esthetics, Dental | 1 | 2023 | 21 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2017 | 395 | 0.200 |
Why?
|
| Methacrylates | 2 | 2020 | 18 | 0.200 |
Why?
|
| Gases | 1 | 2023 | 20 | 0.200 |
Why?
|
| Environmental Pollution | 1 | 2023 | 16 | 0.200 |
Why?
|
| Arthritis, Infectious | 1 | 2004 | 67 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 6 | 2024 | 1084 | 0.200 |
Why?
|
| Cartilage | 1 | 2023 | 51 | 0.200 |
Why?
|
| Hospital Mortality | 6 | 2017 | 1095 | 0.200 |
Why?
|
| Clove Oil | 1 | 2022 | 1 | 0.200 |
Why?
|
| Pharmacies | 1 | 2023 | 15 | 0.200 |
Why?
|
| Crop Production | 1 | 2022 | 1 | 0.200 |
Why?
|
| Psidium | 1 | 2022 | 1 | 0.200 |
Why?
|
| Olive Oil | 1 | 2022 | 24 | 0.200 |
Why?
|
| Synovial Fluid | 1 | 2022 | 17 | 0.200 |
Why?
|
| Ampicillin | 2 | 2024 | 57 | 0.200 |
Why?
|
| Cellulases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Pharmacy | 1 | 2023 | 20 | 0.200 |
Why?
|
| Ciprofloxacin | 2 | 2023 | 69 | 0.200 |
Why?
|
| Anaerobiosis | 1 | 2022 | 15 | 0.200 |
Why?
|
| Silymarin | 1 | 2022 | 1 | 0.200 |
Why?
|
| Rumen | 1 | 2022 | 14 | 0.200 |
Why?
|
| Methane | 1 | 2022 | 18 | 0.200 |
Why?
|
| Diabetic Foot | 1 | 2025 | 167 | 0.190 |
Why?
|
| Hand Strength | 1 | 2022 | 60 | 0.190 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2017 | 336 | 0.190 |
Why?
|
| Burn Units | 1 | 2022 | 11 | 0.190 |
Why?
|
| Ecosystem | 1 | 2023 | 110 | 0.190 |
Why?
|
| American Heart Association | 3 | 2015 | 329 | 0.190 |
Why?
|
| Hexachlorobenzene | 1 | 2022 | 2 | 0.190 |
Why?
|
| Motion | 1 | 2022 | 44 | 0.190 |
Why?
|
| Diffusion | 1 | 2022 | 58 | 0.190 |
Why?
|
| Energy Transfer | 1 | 2022 | 18 | 0.190 |
Why?
|
| Polyethylenes | 1 | 2022 | 6 | 0.190 |
Why?
|
| DDT | 1 | 2022 | 6 | 0.190 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2022 | 14 | 0.190 |
Why?
|
| Metal-Organic Frameworks | 1 | 2022 | 5 | 0.190 |
Why?
|
| Bioreactors | 1 | 2022 | 44 | 0.190 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 76 | 0.190 |
Why?
|
| Logistic Models | 3 | 2014 | 1861 | 0.190 |
Why?
|
| Azithromycin | 2 | 2021 | 46 | 0.190 |
Why?
|
| Neoplasms | 4 | 2024 | 2984 | 0.190 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 69 | 0.190 |
Why?
|
| Diabetes Complications | 2 | 2021 | 204 | 0.190 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 4 | 2024 | 38 | 0.190 |
Why?
|
| Mupirocin | 1 | 2022 | 20 | 0.190 |
Why?
|
| Inpatients | 2 | 2017 | 552 | 0.190 |
Why?
|
| Physical Phenomena | 1 | 2021 | 3 | 0.180 |
Why?
|
| Confidence Intervals | 2 | 2013 | 279 | 0.180 |
Why?
|
| Copper | 2 | 2022 | 73 | 0.180 |
Why?
|
| West Nile Fever | 1 | 2003 | 139 | 0.180 |
Why?
|
| Antitubercular Agents | 2 | 2023 | 265 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 313 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| HeLa Cells | 3 | 2023 | 839 | 0.180 |
Why?
|
| Heart Valves | 2 | 2019 | 54 | 0.180 |
Why?
|
| Phosphorous Acids | 1 | 2021 | 1 | 0.180 |
Why?
|
| Lasers, Excimer | 1 | 2021 | 69 | 0.180 |
Why?
|
| Povidone | 1 | 2021 | 6 | 0.180 |
Why?
|
| Mannose | 2 | 2018 | 27 | 0.180 |
Why?
|
| Refractive Surgical Procedures | 1 | 2021 | 45 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 4 | 2015 | 1340 | 0.180 |
Why?
|
| Myoclonus | 1 | 2021 | 33 | 0.180 |
Why?
|
| Polygonaceae | 1 | 2021 | 1 | 0.180 |
Why?
|
| Piroxicam | 1 | 2021 | 2 | 0.180 |
Why?
|
| Staphylococcus | 1 | 2021 | 69 | 0.180 |
Why?
|
| Child Nutrition Disorders | 1 | 2022 | 77 | 0.180 |
Why?
|
| Biological Dressings | 1 | 2020 | 6 | 0.180 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 2021 | 17 | 0.180 |
Why?
|
| Xylosidases | 1 | 2020 | 1 | 0.180 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 47 | 0.180 |
Why?
|
| Spirochaetales | 1 | 2020 | 6 | 0.170 |
Why?
|
| Sodium Hydroxide | 1 | 2020 | 8 | 0.170 |
Why?
|
| Liposomes | 2 | 2021 | 207 | 0.170 |
Why?
|
| Chloroquine | 1 | 2021 | 32 | 0.170 |
Why?
|
| Onychomycosis | 1 | 2021 | 8 | 0.170 |
Why?
|
| Alkalies | 1 | 2020 | 25 | 0.170 |
Why?
|
| Rifampin | 2 | 2023 | 136 | 0.170 |
Why?
|
| Cardiac Catheterization | 1 | 2005 | 669 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 21 | 0.170 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2020 | 34 | 0.170 |
Why?
|
| Treponema pallidum | 1 | 2020 | 50 | 0.170 |
Why?
|
| Candida | 2 | 2021 | 84 | 0.170 |
Why?
|
| Mice | 11 | 2024 | 18929 | 0.170 |
Why?
|
| Selenium | 1 | 2020 | 17 | 0.170 |
Why?
|
| Acellular Dermis | 1 | 2020 | 7 | 0.170 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 21 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 90 | 0.170 |
Why?
|
| Wettability | 1 | 2020 | 2 | 0.170 |
Why?
|
| Breast Implants | 1 | 2020 | 31 | 0.170 |
Why?
|
| Leishmania tropica | 1 | 2020 | 2 | 0.170 |
Why?
|
| Physicians' Offices | 1 | 2020 | 10 | 0.170 |
Why?
|
| Membranes | 1 | 2020 | 19 | 0.170 |
Why?
|
| Voriconazole | 2 | 2014 | 34 | 0.170 |
Why?
|
| Ketoprofen | 1 | 2020 | 1 | 0.170 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 22 | 0.170 |
Why?
|
| Spine | 1 | 2021 | 147 | 0.170 |
Why?
|
| Teratogens | 1 | 2020 | 86 | 0.160 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2020 | 6 | 0.160 |
Why?
|
| Facial Recognition | 1 | 2020 | 5 | 0.160 |
Why?
|
| Naproxen | 1 | 2020 | 20 | 0.160 |
Why?
|
| Microinjections | 1 | 2020 | 51 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 2139 | 0.160 |
Why?
|
| Nanotubes | 1 | 2020 | 18 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 306 | 0.160 |
Why?
|
| Encephalitis | 1 | 2021 | 122 | 0.160 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 527 | 0.160 |
Why?
|
| Syphilis | 1 | 2020 | 98 | 0.160 |
Why?
|
| Colony Count, Microbial | 1 | 2020 | 86 | 0.160 |
Why?
|
| Operative Time | 2 | 2019 | 189 | 0.160 |
Why?
|
| Enterococcus faecalis | 2 | 2018 | 50 | 0.160 |
Why?
|
| Facial Expression | 1 | 2020 | 28 | 0.160 |
Why?
|
| Ferric Compounds | 1 | 2020 | 41 | 0.160 |
Why?
|
| Disulfides | 1 | 2020 | 84 | 0.160 |
Why?
|
| Light | 1 | 2020 | 183 | 0.160 |
Why?
|
| Splenic Infarction | 1 | 2019 | 4 | 0.160 |
Why?
|
| Carnobacteriaceae | 1 | 2019 | 2 | 0.160 |
Why?
|
| Needles | 1 | 2020 | 51 | 0.160 |
Why?
|
| Mammaplasty | 1 | 2020 | 54 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2013 | 320 | 0.160 |
Why?
|
| Disease Vectors | 1 | 2019 | 22 | 0.160 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2019 | 14 | 0.160 |
Why?
|
| Biopolymers | 1 | 2019 | 21 | 0.160 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 637 | 0.160 |
Why?
|
| Enterococcus | 1 | 2019 | 31 | 0.160 |
Why?
|
| Emulsifying Agents | 1 | 2019 | 3 | 0.160 |
Why?
|
| Macrophages | 3 | 2020 | 697 | 0.160 |
Why?
|
| Chlorpromazine | 1 | 2019 | 13 | 0.160 |
Why?
|
| Transducers | 1 | 2019 | 26 | 0.160 |
Why?
|
| Itraconazole | 1 | 2019 | 24 | 0.160 |
Why?
|
| Histoplasma | 1 | 2019 | 31 | 0.160 |
Why?
|
| Flucytosine | 1 | 2019 | 17 | 0.160 |
Why?
|
| Rats, Wistar | 1 | 2020 | 398 | 0.160 |
Why?
|
| Cryptococcus neoformans | 1 | 2019 | 23 | 0.160 |
Why?
|
| Paromomycin | 1 | 2019 | 3 | 0.150 |
Why?
|
| Domperidone | 1 | 2019 | 4 | 0.150 |
Why?
|
| Wireless Technology | 1 | 2019 | 13 | 0.150 |
Why?
|
| Immunocompetence | 1 | 2019 | 33 | 0.150 |
Why?
|
| Cleft Palate | 1 | 2021 | 153 | 0.150 |
Why?
|
| Sonication | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2019 | 6 | 0.150 |
Why?
|
| Heart Conduction System | 1 | 2020 | 145 | 0.150 |
Why?
|
| Pelvic Infection | 1 | 2018 | 4 | 0.150 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 30 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2019 | 47 | 0.150 |
Why?
|
| Health Resources | 1 | 2020 | 127 | 0.150 |
Why?
|
| Cosmetics | 1 | 2018 | 9 | 0.150 |
Why?
|
| Facial Injuries | 1 | 2019 | 21 | 0.150 |
Why?
|
| Malnutrition | 1 | 2022 | 222 | 0.150 |
Why?
|
| Titanium | 1 | 2018 | 25 | 0.150 |
Why?
|
| Taste | 1 | 2018 | 33 | 0.150 |
Why?
|
| Metagenomics | 1 | 2019 | 110 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 241 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 237 | 0.150 |
Why?
|
| Phytotherapy | 1 | 2019 | 50 | 0.150 |
Why?
|
| Spinal Cord | 1 | 2020 | 275 | 0.150 |
Why?
|
| Pectins | 3 | 2024 | 9 | 0.150 |
Why?
|
| Viral Load | 1 | 2020 | 410 | 0.150 |
Why?
|
| Dendrimers | 1 | 2018 | 10 | 0.150 |
Why?
|
| Doxycycline | 1 | 2019 | 121 | 0.150 |
Why?
|
| Oligosaccharides | 1 | 2019 | 78 | 0.150 |
Why?
|
| Goldenhar Syndrome | 1 | 2018 | 14 | 0.150 |
Why?
|
| Viscosity | 3 | 2022 | 42 | 0.140 |
Why?
|
| Pharmacists | 1 | 2019 | 105 | 0.140 |
Why?
|
| Peritonitis | 1 | 2018 | 78 | 0.140 |
Why?
|
| Polyethylene | 1 | 2018 | 15 | 0.140 |
Why?
|
| Butadienes | 1 | 2018 | 21 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 283 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 45 | 0.140 |
Why?
|
| Niacinamide | 1 | 2018 | 31 | 0.140 |
Why?
|
| Pain Management | 1 | 2020 | 202 | 0.140 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 132 | 0.140 |
Why?
|
| Polyethyleneimine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Meglumine | 1 | 2017 | 16 | 0.140 |
Why?
|
| Palladium | 1 | 2017 | 15 | 0.140 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Ibuprofen | 1 | 2018 | 42 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2019 | 72 | 0.140 |
Why?
|
| Pregnancy | 4 | 2020 | 7593 | 0.140 |
Why?
|
| Rhizomucor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Cardiac Electrophysiology | 1 | 2017 | 14 | 0.140 |
Why?
|
| Spatial Analysis | 1 | 2017 | 26 | 0.140 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 218 | 0.140 |
Why?
|
| Stem Cells | 2 | 2020 | 747 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 56 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 201 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2020 | 415 | 0.140 |
Why?
|
| Aortic Valve | 2 | 2020 | 467 | 0.140 |
Why?
|
| Equipment and Supplies | 1 | 2017 | 28 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2018 | 86 | 0.140 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.140 |
Why?
|
| Fundus Oculi | 1 | 2017 | 64 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 106 | 0.130 |
Why?
|
| Recurrence | 4 | 2018 | 1469 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 43 | 0.130 |
Why?
|
| Trypanocidal Agents | 1 | 2017 | 31 | 0.130 |
Why?
|
| Suction | 1 | 2017 | 56 | 0.130 |
Why?
|
| Minocycline | 1 | 2017 | 42 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2019 | 3408 | 0.130 |
Why?
|
| Emotions | 1 | 2020 | 366 | 0.130 |
Why?
|
| DNA | 2 | 2022 | 1675 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1033 | 0.130 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4754 | 0.130 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 32 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 78 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2014 | 328 | 0.130 |
Why?
|
| Face | 1 | 2018 | 189 | 0.130 |
Why?
|
| Genomics | 1 | 2025 | 1677 | 0.130 |
Why?
|
| Steroids | 2 | 2021 | 211 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 343 | 0.130 |
Why?
|
| Electronic Health Records | 3 | 2018 | 804 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 213 | 0.130 |
Why?
|
| Memory | 1 | 2020 | 358 | 0.130 |
Why?
|
| Hirudins | 1 | 2016 | 40 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 638 | 0.130 |
Why?
|
| Temperature | 3 | 2022 | 325 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 202 | 0.130 |
Why?
|
| Vibrio cholerae non-O1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Actinomycetales Infections | 1 | 2016 | 15 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 297 | 0.130 |
Why?
|
| Vibrio Infections | 1 | 2016 | 16 | 0.120 |
Why?
|
| Enterobacteriaceae | 1 | 2016 | 41 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1419 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 175 | 0.120 |
Why?
|
| Global Health | 1 | 2021 | 621 | 0.120 |
Why?
|
| Mycoses | 1 | 2017 | 117 | 0.120 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2016 | 59 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 169 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2020 | 409 | 0.120 |
Why?
|
| Surface Properties | 3 | 2022 | 96 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 251 | 0.120 |
Why?
|
| Tablets | 3 | 2021 | 36 | 0.120 |
Why?
|
| Gout | 1 | 2019 | 167 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 188 | 0.120 |
Why?
|
| Lipids | 2 | 2019 | 565 | 0.120 |
Why?
|
| Debridement | 2 | 2007 | 92 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 188 | 0.120 |
Why?
|
| Drug Compounding | 3 | 2020 | 43 | 0.120 |
Why?
|
| Intestines | 1 | 2019 | 601 | 0.120 |
Why?
|
| Calorimetry, Differential Scanning | 3 | 2020 | 8 | 0.120 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2015 | 18 | 0.120 |
Why?
|
| Mitral Valve Prolapse | 1 | 2015 | 35 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 151 | 0.120 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 723 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 296 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 214 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 1830 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 66 | 0.110 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 96 | 0.110 |
Why?
|
| Acute Disease | 1 | 2017 | 1182 | 0.110 |
Why?
|
| Urologic Surgical Procedures | 1 | 2014 | 59 | 0.110 |
Why?
|
| Echinocandins | 1 | 2014 | 44 | 0.110 |
Why?
|
| Foreign-Body Migration | 1 | 2014 | 61 | 0.110 |
Why?
|
| Endoscopy | 1 | 2016 | 280 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1404 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 389 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2021 | 739 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 135 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 312 | 0.110 |
Why?
|
| Chloramphenicol | 2 | 2024 | 25 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 760 | 0.110 |
Why?
|
| Child, Preschool | 4 | 2025 | 14865 | 0.100 |
Why?
|
| Florida | 1 | 2013 | 79 | 0.100 |
Why?
|
| Ureteral Obstruction | 1 | 2014 | 105 | 0.100 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 280 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 164 | 0.100 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2014 | 105 | 0.100 |
Why?
|
| Causality | 1 | 2013 | 94 | 0.100 |
Why?
|
| Rare Diseases | 1 | 2015 | 208 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 829 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 612 | 0.100 |
Why?
|
| ROC Curve | 1 | 2014 | 603 | 0.100 |
Why?
|
| Furunculosis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Chills | 1 | 2012 | 6 | 0.100 |
Why?
|
| Adsorption | 2 | 2025 | 37 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2019 | 804 | 0.100 |
Why?
|
| Reoperation | 2 | 2017 | 856 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 3087 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2015 | 825 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 460 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2016 | 520 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 3985 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 314 | 0.090 |
Why?
|
| Seizures | 1 | 2017 | 887 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 834 | 0.090 |
Why?
|
| Morbidity | 3 | 2020 | 255 | 0.090 |
Why?
|
| Biomimetics | 2 | 2023 | 18 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1388 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2559 | 0.090 |
Why?
|
| Acyclovir | 1 | 2011 | 47 | 0.090 |
Why?
|
| Acrylamides | 2 | 2023 | 25 | 0.090 |
Why?
|
| Infant | 3 | 2022 | 13235 | 0.090 |
Why?
|
| Spinal Diseases | 1 | 2011 | 46 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 353 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2016 | 519 | 0.090 |
Why?
|
| Exanthema | 1 | 2012 | 71 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 115 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2013 | 329 | 0.090 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 6 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 256 | 0.090 |
Why?
|
| Models, Molecular | 3 | 2020 | 1147 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 311 | 0.090 |
Why?
|
| Metronidazole | 1 | 2011 | 149 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 165 | 0.090 |
Why?
|
| Gram-Positive Cocci | 1 | 2010 | 3 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 335 | 0.090 |
Why?
|
| Aspirin | 1 | 2012 | 231 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2014 | 539 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 1468 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 34 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1714 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1099 | 0.080 |
Why?
|
| Porosity | 2 | 2020 | 44 | 0.080 |
Why?
|
| Oxygen | 2 | 2022 | 578 | 0.080 |
Why?
|
| Powder Diffraction | 2 | 2021 | 2 | 0.080 |
Why?
|
| Drug Stability | 2 | 2020 | 62 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 943 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2013 | 378 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2021 | 151 | 0.080 |
Why?
|
| Tissue Engineering | 2 | 2023 | 180 | 0.080 |
Why?
|
| Age of Onset | 1 | 2011 | 627 | 0.080 |
Why?
|
| Myocarditis | 1 | 2010 | 132 | 0.080 |
Why?
|
| Case Management | 1 | 2009 | 21 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2020 | 139 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 335 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 2021 | 490 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 555 | 0.070 |
Why?
|
| Biomarkers | 1 | 2018 | 3411 | 0.070 |
Why?
|
| Mannose-Binding Lectins | 2 | 2019 | 26 | 0.070 |
Why?
|
| Molecular Docking Simulation | 2 | 2021 | 127 | 0.070 |
Why?
|
| Poxviridae | 1 | 2008 | 4 | 0.070 |
Why?
|
| Sheep Diseases | 1 | 2008 | 7 | 0.070 |
Why?
|
| Stents | 1 | 2014 | 880 | 0.070 |
Why?
|
| Erythrocytes | 2 | 2020 | 232 | 0.070 |
Why?
|
| Phenotype | 1 | 2018 | 4574 | 0.070 |
Why?
|
| Ecthyma, Contagious | 1 | 2008 | 5 | 0.070 |
Why?
|
| Skin Diseases, Infectious | 1 | 2008 | 25 | 0.070 |
Why?
|
| Lectins, C-Type | 2 | 2019 | 74 | 0.070 |
Why?
|
| Zoonoses | 1 | 2008 | 52 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2011 | 427 | 0.070 |
Why?
|
| Fungi | 2 | 2021 | 75 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1608 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2017 | 1583 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2018 | 89 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2022 | 629 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2021 | 960 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2020 | 1303 | 0.070 |
Why?
|
| Colon | 2 | 2020 | 373 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 327 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 236 | 0.060 |
Why?
|
| Polyvinyl Chloride | 1 | 2025 | 2 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 92 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 498 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2020 | 708 | 0.060 |
Why?
|
| Acrylic Resins | 1 | 2025 | 12 | 0.060 |
Why?
|
| Garlic | 1 | 2025 | 1 | 0.060 |
Why?
|
| Urogenital System | 1 | 2005 | 36 | 0.060 |
Why?
|
| Monkeypox virus | 1 | 2025 | 5 | 0.060 |
Why?
|
| Lung Diseases, Fungal | 1 | 2005 | 32 | 0.060 |
Why?
|
| Motion Sickness | 1 | 2005 | 10 | 0.060 |
Why?
|
| Corynebacterium Infections | 1 | 2005 | 5 | 0.060 |
Why?
|
| Biodegradation, Environmental | 1 | 2024 | 13 | 0.060 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 501 | 0.060 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2005 | 37 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2020 | 1031 | 0.060 |
Why?
|
| Genotype | 2 | 2021 | 2719 | 0.060 |
Why?
|
| Patient Safety | 2 | 2020 | 436 | 0.060 |
Why?
|
| Sudden Infant Death | 1 | 2005 | 36 | 0.060 |
Why?
|
| Polyesters | 1 | 2024 | 43 | 0.060 |
Why?
|
| Phototherapy | 1 | 2024 | 39 | 0.060 |
Why?
|
| Salt-Tolerant Plants | 1 | 2024 | 1 | 0.060 |
Why?
|
| Laccase | 1 | 2024 | 4 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1558 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2024 | 35 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2022 | 562 | 0.060 |
Why?
|
| Nanofibers | 1 | 2024 | 20 | 0.050 |
Why?
|
| Organs at Risk | 1 | 2024 | 41 | 0.050 |
Why?
|
| Shoulder Injuries | 1 | 2004 | 11 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 91 | 0.050 |
Why?
|
| Paralysis | 1 | 2003 | 29 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2024 | 146 | 0.050 |
Why?
|
| Registries | 3 | 2018 | 1582 | 0.050 |
Why?
|
| Spectrometry, Gamma | 1 | 2023 | 1 | 0.050 |
Why?
|
| Thorium | 1 | 2023 | 1 | 0.050 |
Why?
|
| Potassium Radioisotopes | 1 | 2023 | 7 | 0.050 |
Why?
|
| Cefotaxime | 1 | 2023 | 39 | 0.050 |
Why?
|
| Apoptosis | 2 | 2024 | 1928 | 0.050 |
Why?
|
| Cesium Radioisotopes | 1 | 2023 | 8 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 1240 | 0.050 |
Why?
|
| Cefoxitin | 1 | 2023 | 5 | 0.050 |
Why?
|
| Methylcellulose | 1 | 2023 | 6 | 0.050 |
Why?
|
| Linezolid | 1 | 2023 | 27 | 0.050 |
Why?
|
| Erythromycin | 1 | 2023 | 21 | 0.050 |
Why?
|
| Clindamycin | 1 | 2023 | 42 | 0.050 |
Why?
|
| Suspensions | 1 | 2022 | 9 | 0.050 |
Why?
|
| Skin Absorption | 1 | 2022 | 7 | 0.050 |
Why?
|
| Aflatoxin B1 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Electromyography | 1 | 2003 | 141 | 0.050 |
Why?
|
| Salinity | 1 | 2022 | 3 | 0.050 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2022 | 13 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2024 | 780 | 0.050 |
Why?
|
| Micelles | 1 | 2022 | 21 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 281 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2022 | 55 | 0.050 |
Why?
|
| Emulsions | 1 | 2022 | 70 | 0.050 |
Why?
|
| Risk | 1 | 2005 | 781 | 0.050 |
Why?
|
| Dehydration | 1 | 2022 | 41 | 0.050 |
Why?
|
| Galactans | 1 | 2022 | 3 | 0.050 |
Why?
|
| Plant Gums | 1 | 2022 | 3 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2005 | 195 | 0.050 |
Why?
|
| Chondroitin Sulfates | 1 | 2022 | 15 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2022 | 142 | 0.050 |
Why?
|
| DNA, Single-Stranded | 1 | 2022 | 76 | 0.050 |
Why?
|
| Magnetic Phenomena | 1 | 2022 | 6 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2005 | 111 | 0.050 |
Why?
|
| Mannans | 1 | 2022 | 15 | 0.050 |
Why?
|
| Exodeoxyribonucleases | 1 | 2022 | 52 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2022 | 94 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2022 | 99 | 0.050 |
Why?
|
| Keratins | 1 | 2022 | 52 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 1212 | 0.050 |
Why?
|
| Agricultural Irrigation | 1 | 2022 | 2 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2022 | 115 | 0.050 |
Why?
|
| Food Chain | 1 | 2022 | 11 | 0.050 |
Why?
|
| Crops, Agricultural | 1 | 2022 | 20 | 0.050 |
Why?
|
| Biomimetic Materials | 1 | 2021 | 14 | 0.050 |
Why?
|
| Floods | 1 | 2022 | 18 | 0.050 |
Why?
|
| Genes, rRNA | 1 | 2021 | 19 | 0.050 |
Why?
|
| Colistin | 1 | 2022 | 33 | 0.050 |
Why?
|
| Vegetables | 1 | 2024 | 274 | 0.050 |
Why?
|
| Animal Feed | 1 | 2022 | 83 | 0.050 |
Why?
|
| Rheology | 1 | 2021 | 35 | 0.050 |
Why?
|
| Streptozocin | 1 | 2021 | 28 | 0.050 |
Why?
|
| 3T3-L1 Cells | 1 | 2021 | 58 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 593 | 0.040 |
Why?
|
| Thinness | 1 | 2022 | 79 | 0.040 |
Why?
|
| Transportation | 1 | 2021 | 29 | 0.040 |
Why?
|
| Elasticity | 1 | 2021 | 93 | 0.040 |
Why?
|
| Age Factors | 2 | 2021 | 2954 | 0.040 |
Why?
|
| Palate, Soft | 1 | 2021 | 15 | 0.040 |
Why?
|
| Bread | 1 | 2021 | 5 | 0.040 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2021 | 9 | 0.040 |
Why?
|
| Air Microbiology | 1 | 2021 | 12 | 0.040 |
Why?
|
| Polymyxin B | 1 | 2022 | 47 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2023 | 306 | 0.040 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2020 | 8 | 0.040 |
Why?
|
| Speech Disorders | 1 | 2021 | 48 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 238 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2004 | 420 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2025 | 1236 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 109 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2020 | 31 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 129 | 0.040 |
Why?
|
| Speech | 1 | 2021 | 78 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2022 | 270 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 81 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 233 | 0.040 |
Why?
|
| Ammonium Sulfate | 1 | 2020 | 12 | 0.040 |
Why?
|
| Thermogravimetry | 1 | 2020 | 6 | 0.040 |
Why?
|
| Polymerization | 1 | 2020 | 15 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2021 | 134 | 0.040 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 68 | 0.040 |
Why?
|
| Penicillins | 1 | 2020 | 153 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2020 | 32 | 0.040 |
Why?
|
| Thrombosis | 1 | 2005 | 544 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 67 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 392 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 138 | 0.040 |
Why?
|
| Sulfasalazine | 1 | 2019 | 4 | 0.040 |
Why?
|
| Genes, Mitochondrial | 1 | 2019 | 21 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 186 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2021 | 180 | 0.040 |
Why?
|
| Gels | 1 | 2019 | 71 | 0.040 |
Why?
|
| Muramidase | 1 | 2019 | 99 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 138 | 0.040 |
Why?
|
| Chitin | 1 | 2019 | 5 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 225 | 0.040 |
Why?
|
| Chemical Phenomena | 1 | 2019 | 87 | 0.040 |
Why?
|
| Chemical Fractionation | 1 | 2019 | 14 | 0.040 |
Why?
|
| Dynamic Light Scattering | 1 | 2019 | 9 | 0.040 |
Why?
|
| Hypoxia | 1 | 2021 | 267 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 49 | 0.040 |
Why?
|
| Leishmania donovani | 1 | 2019 | 24 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 213 | 0.040 |
Why?
|
| Australia | 1 | 2019 | 191 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 104 | 0.040 |
Why?
|
| Abdomen, Acute | 1 | 2018 | 14 | 0.040 |
Why?
|
| Spectrum Analysis | 1 | 2019 | 69 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2018 | 111 | 0.040 |
Why?
|
| Professional Role | 1 | 2019 | 74 | 0.040 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 74 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2019 | 40 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 562 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 341 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 135 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 908 | 0.040 |
Why?
|
| Powders | 1 | 2018 | 28 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 343 | 0.040 |
Why?
|
| Adhesiveness | 1 | 2018 | 14 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 153 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 373 | 0.040 |
Why?
|
| Uric Acid | 1 | 2019 | 109 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2019 | 231 | 0.040 |
Why?
|
| Nitrophenols | 1 | 2017 | 16 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2019 | 319 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 98 | 0.040 |
Why?
|
| Citrates | 1 | 2017 | 24 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 156 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 916 | 0.030 |
Why?
|
| Hemolysis | 1 | 2018 | 114 | 0.030 |
Why?
|
| Atrophy | 1 | 2018 | 231 | 0.030 |
Why?
|
| Receptors, Scavenger | 1 | 2017 | 3 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 80 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 15 | 0.030 |
Why?
|
| Permeability | 1 | 2018 | 131 | 0.030 |
Why?
|
| Catalysis | 1 | 2017 | 141 | 0.030 |
Why?
|
| Plants | 1 | 2017 | 52 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 607 | 0.030 |
Why?
|
| Gold | 1 | 2017 | 57 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 3863 | 0.030 |
Why?
|
| United Kingdom | 1 | 2018 | 241 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2018 | 400 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2021 | 539 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 396 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1350 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 92 | 0.030 |
Why?
|
| Biological Transport | 1 | 2017 | 367 | 0.030 |
Why?
|
| Drainage | 1 | 2018 | 264 | 0.030 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 81 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2017 | 67 | 0.030 |
Why?
|
| Cornea | 1 | 2021 | 595 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 362 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2019 | 814 | 0.030 |
Why?
|
| Hematoma | 1 | 2017 | 93 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 263 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 464 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 260 | 0.030 |
Why?
|
| Triglycerides | 1 | 2019 | 616 | 0.030 |
Why?
|
| Serotyping | 1 | 2016 | 178 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2016 | 104 | 0.030 |
Why?
|
| Streptococcus | 1 | 2016 | 63 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 154 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 466 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2018 | 483 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 609 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 136 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 562 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1156 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 2014 | 32 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2014 | 20 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 487 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 252 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 394 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1307 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2014 | 42 | 0.030 |
Why?
|
| Peripartum Period | 1 | 2014 | 29 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 203 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 1 | 2014 | 38 | 0.030 |
Why?
|
| Maternal Mortality | 1 | 2014 | 81 | 0.030 |
Why?
|
| Palivizumab | 1 | 2013 | 48 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 1411 | 0.030 |
Why?
|
| Ureter | 1 | 2014 | 100 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2014 | 180 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 276 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 252 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2015 | 182 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Sweating | 1 | 2012 | 7 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2019 | 3131 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2013 | 176 | 0.020 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2013 | 153 | 0.020 |
Why?
|
| Physicians | 1 | 2019 | 640 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 1136 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2855 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 294 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 822 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 198 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 398 | 0.020 |
Why?
|
| Leukocytes | 1 | 2012 | 216 | 0.020 |
Why?
|
| Drug Implants | 1 | 2010 | 44 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1706 | 0.020 |
Why?
|
| New York | 1 | 2010 | 72 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 569 | 0.020 |
Why?
|
| Critical Illness | 1 | 2014 | 628 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 3223 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 292 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2008 | 1 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2008 | 66 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 2160 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2286 | 0.020 |
Why?
|
| Lung | 1 | 2014 | 1570 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 496 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 346 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 997 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 3153 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 3960 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1887 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 4915 | 0.010 |
Why?
|